Navigation Links
Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
Date:12/8/2007

ed the injectable suspension formulation and 13 received the Cremophor-containing formulation.

To date, the response rate at the 340 mg/m2 dose is lower than that in the earlier, dose-escalating group that received doses of tanespimycin between 100 and 275 mg/m2.

The combination of tanespimycin and bortezomib was well-tolerated. There was no increase in toxicity with the injectable suspension formulation compared to the Cremophor-containing formulation observed with the tanespimycin plus bortezomib combination dosed at 340 mg/m2 and 1.3 mg/m2, respectively. Common toxicities were similar for the two tanespimycin formulations. Common tanespimycin toxicities (primarily Grade 1-2) were gastrointestinal (diarrhea, nausea, vomiting), fatigue, reversible increased liver function tests (LFT), dizziness, headache, insomnia and musculoskeletal malaise. Grade 3 tanespimycin toxicities were limited to diarrhea, fatigue and increased LFT. No cardiovascular toxicity was observed.

Common toxicities associated with bortezomib included thrombocytopenia (Grade 3-4 at 1.3 mg/m2) and neuropathy (Grade 1-2, at 1.3 mg/m2). A lower than anticipated rate of neuropathy was observed in the tanespimycin plus bortezomib combination, and no patient experienced a Grade 3 neuropathy. In prior bortezomib trials (the SUMMIT and CREST trials), 13% Grade 3 neuropathy was observed. This observation supports the hypothesis that treatment with tanespimycin exerts a neuroprotective effect.

Tanespimycin in Myeloma Evaluation (TIME) Program

The Phase 1b trial is ongoing and multiple patients remain on study. Kosan intends to complete the trial and report the final data at a later date.

Kosan's TIME registration program has been opened, with the initiation of the TIME-2 trial. TIME-2 is a Phase 2/3 trial in patients with relapsed- refractory multiple myeloma. The multi-site, open-label trial is being conducted primarily in the US and Europe. TIME-2 is designed to c
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
2. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
3. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
8. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
9. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
10. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... researchers with EDP Biotech Corporation (EDP) have captured ... a simple blood test to detect early-stage colon ... its pre-clinical trials for the ColoMarker(TM) assay, EDP ... and all aspects of its use. Via ... cancer in its earliest, most curable stages. ,, ...
(Date:12/15/2009)... Tenn., Dec. 15 Cumberland Pharmaceuticals ... announced new top-line results for a patient ... Oral Solution, a prescription laxative packaged as a ... forms. ,, Kristalose is the only prescription-strength laxative ... period, 50 patients with a recent diagnosis of ...
(Date:12/15/2009)... Dec. 15 Today,s New ... "Plan for Kidney Drugs Spurs Division," illustrates an ... in kidney patients continuing to be deprived of ... Medicare program limit. ,, As Congress is poised ... preserve the lives of transplant kidney recipients, behind-the-scenes ...
Breaking Medicine Technology:Researchers Announce Medical Breakthrough with Simple, Inexpensive Blood Test for Colon Cancer 2Kristalose(R) Preferred by Patients With Chronic Constipation Compared to Similar Products in a Recent Study 2Kristalose(R) Preferred by Patients With Chronic Constipation Compared to Similar Products in a Recent Study 3AST Concerned That Kidney Transplant Patients May Suffer Politics As Usual in Capitol Hill Health Care Reform Debate 2Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results 6197 1Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results 6197 2Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results 6197 3Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results 6197 4Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results 6197 5Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results 6197 6Chimerix to Present at Two Upcoming Investor Conferences 6195 1Chimerix to Present at Two Upcoming Investor Conferences 6195 2Behavior modification could ease concerns about nanoparticles 10701 1Behavior modification could ease concerns about nanoparticles 10701 2
... and Specific Molecular Structures Needed for siRNA ... ... Silence Therapeutics plc,(AIM:SLN) Europe,s leading RNAi-focused biotechnology company, today,comments on ... via TLR3" Mark E.,Kleinman, et. al., and Molecules and Cells(2) ...
... Data from five studies sponsored,by Ortho Biotech ... Kidney,Foundation (NKF) 2008 Spring Clinical Meetings from April ... (Epoetin alfa)., The data include studies that ... and darbepoetin alfa (DARB), evaluate medical costs,related to ...
Other Medicine Technology:Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach 2Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach 3Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach 4Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 2Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 3Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 4Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 5Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 6
(Date:12/15/2009)... PLAINS, N.Y., Dec. 15 Team In ... groundbreaking charity sports training program, has ... to support blood cancer research and patient services. ... been the pre-eminent charity endurance sports training program, ... marathon, half marathon, triathlon, 100-mile century cycle ride ...
(Date:12/15/2009)... are the remarks by Lanny A. Breuer, ... the Medicare Fraud Strike Force press conference: ,, ... the enormous effort everyone at HHS is putting ... Departments have and will continue to accomplish significant ... in fighting Medicare fraud in South Florida, Los ...
(Date:12/15/2009)... North American application activity for individually ... according to the MIB Life Index(SM) . ... the past three months have lifted year-to-date (YTD) ... to flat at November,s close, -0.1%. "It ... the benefits available from life insurance," says Stacy ...
(Date:12/15/2009)... lll. Physical activity is known to reduce depression ... new study indicates that this effect stems from an ... his or her ability to achieve certain physical ... Psychosomatic Medicine . , "We base our arguments on ... a professor of kinesiology and community health at the ...
(Date:12/15/2009)... help older adults delay or reverse declining brain ... at the Johns Hopkins Bloomberg School of Public ... researchers found that seniors participating in a youth ... that support cognitive abilities important to planning and ... first of its kind to demonstrate that valuable ...
Breaking Medicine News(10 mins):Health News:$1 Billion - For Charity! 2Health News:$1 Billion - For Charity! 3Health News:Remarks by Lanny A. Breuer, Assistant Attorney General for the Criminal Division, at the Medicare Fraud Strike Force Press Conference 2Health News:Remarks by Lanny A. Breuer, Assistant Attorney General for the Criminal Division, at the Medicare Fraud Strike Force Press Conference 3Health News:MIB Life Index Reports North American Life Insurance Activity Up 3.9% in November 2Health News:MIB Life Index Reports North American Life Insurance Activity Up 3.9% in November 3Health News:Mastery of physical goals lessens disease-related depression and fatigue 2Health News:For older adults, participating in social service activities can improve brain functions 2
... play a key role in regulating cell death, a Queen’s ... scientists //that calpain may be used to promote cell death ... cell death such as in neuronal cells in the case ... of Pathology and Molecular Medicine with the Cancer Biology and ...
... of free personal care for the elderly was planned as ... the dignity and security //for everyone in old age. But ... of funding. Many medical councils are alleging that they have ... ,Earlier this week it was reported that more than 200 ...
... (Partners) and the SRM Institute of Science and Technology, ... care. // ,The MoU aimed at developing ... opportunities for its medical and nursing staff both in ... P Sathyanarayanan, said., ,The MoU was signed in ...
... to safeguard the health of pregnant women canned tuna to ... it! ,The actions and steps are being ... as much mercury as white tuna., ,Highlighting the ... in the bloodstream may harm developing nervous systems., ...
... in Mumbai with both Rahul Mahajan, now being treated in ... have supplied// him drugs, being known faces in the party ... as lifestyle drugs,are a rage with the rich and the ... rampant in party circuits or private,functions here," said a senior ...
... whose latest flick 'Fanaa' could not be released in Gujarat ... today ruled out apologising for his remarks even if it ... media at his Bandra residence, the actor said there was ... had said what the Supreme Court had earlier stated in ...
Other Medicine News:Health News:Protein’s role in regulating cell death sets direction for Alzheimer’s, Parkinson’s and cancer resea 2Health News:Drugs Part of Mumbai High Life 2
Fluoro done? Get rid of your apron quickly and easily without breaking the sterile field. A shoulder drop-away can also be used with our Stretchy-back and cummmberbund aprons. Shoulder pads and hangi...
Open armhole design with Velcro release enables removal without compromising sterile field. Loops attached at shoulders for proper hanging & storage...
This apron provides full protection all the way around. Extra wide Velcro strips provide many adjustments and a secure fit....
Unique criss-cross strapping distributes weight evenly over the torso for ultimate comfort and flexibility. Fully adjustable 2 inch belt and buckle for easy front closure....
Medicine Products: